RCAMU
ACAD icon

Rothschild & Co Asset Management US’s Acadia Pharmaceuticals ACAD Stock Holding History

Rothschild & Co Asset Management US’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-26,289
Closed -$591K – 372
2018
Q1 		$591K Buy
+26,289
New +$728K 0.01% 347

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Rothschild & Co Asset Management US's ACAD Position: Q2 2018 in Review

Rothschild & Co Asset Management US sold out of Acadia Pharmaceuticals (ACAD) in Q2 2018, closing a stake of 26,289 shares — an estimated $591K sold.

Rothschild & Co Asset Management US first reported a position in ACAD in Q1 2018 and held it in 1 quarter. The position peaked at $591K in Q1 2018. 187 funds tracked by Wall St. Rank hold ACAD as of Q2 2018.

  • Rothschild & Co Asset Management US reported no remaining Acadia Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 26,289 Acadia Pharmaceuticals shares in Q2 2018, an estimated $591K.
  • Rothschild & Co Asset Management US first reported a position in Acadia Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Rothschild & Co Asset Management US's Acadia Pharmaceuticals position peaked at $591K in Q1 2018.
  • 187 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2018.

Based on Rothschild & Co Asset Management US's 13F filing for Q2 2018, filed 7 Aug 2018.